Selegiline orally disintegrating tablets

Drug Profile

Selegiline orally disintegrating tablets

Alternative Names: Xilopar; Zelapar

Latest Information Update: 20 Dec 2013

Price : $50

At a glance

  • Originator RP Scherer
  • Class Antidementias; Antidepressants; Antiparkinsonians; Phenethylamines
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
  • 18 Jul 2006 Launched for Parkinson's disease in USA (PO)
  • 15 Jun 2006 Registered for Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top